RAD51 and neoplasm: Therefore, the detection of RAD51 foci by IHC and IF, in ex vivo samples or in tumor biopsies during neoadjuvant therapy, may be predictive of HR defects and sensitivity to PARPi, given that PARP inhibition or loss results in an increasing RAD51 foci formation in HR intact cells [167].